Claims for Patent: 9,316,647

Summary for Patent: 9,316,647

Title:	Aptamers and diagnostic methods for detecting the EGF receptor
Abstract:	The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers.
Inventor(s):	Nikrad; Malti P. (Boulder, CO), Gawande; Bharat Nathu (Lafayette, CO)
Assignee:	SomaLogic, Inc. (Boulder, CO)
Application Number:	14/365,332
Patent Claims:	1. An aptamer comprising the nucleotide sequence: XGANNGNNYGANNCNN (SEQ ID NO: 55); wherein X is a G, C or A; Y is a G or A; and N is, independently a 5-position modified 2'-deoxyuridine selected from the group consisting of 5-(N-benzylcarboxyamide)-2'-deoxyuracilyl, 5-(N-isobutylcarboxyamide)-2'-deoxyuridine, 5-(N-tryptaminocarboxyamide)-2'-deoxyuridine, 5-(N-[1-(3-trimethylamonium) propyl]carboxyamide)-2'-deoxyuridine chloride, 5-(N-naphthylmethylcarboxamide)-2'-deoxyuridine, and 5-(N-[1-(2,3-dihydroxypropyl)]carboxyamide)-2'-deoxyuridine. 2. The aptamer of claim 1, wherein said 5-position modified 2'-deoxyuridine is a 5-(N-benzylcarboxyamide)-2'-deoxyuridine (BndU). 3. The aptamer of claim 1, wherein the aptamer is capable of binding to Epidermal Growth Factor receptor (EGFR). 4. The aptamer of claim 3, wherein the binding of the aptamer to EGFR is reduced in a dose-dependent manner based on the presence of an EGFR antagonist. 5. The aptamer of claim 4, wherein the EGFR antagonist is selected from the group consisting of cetuximab and panitumumab. 6. The aptamer of claim 4, wherein the K.sub.d of the aptamer to EGFR is at least 10-fold greater based on the presence of the EGFR antagonist relative to the K.sub.d of the aptamer to free EGFR. 7. The aptamer of claim 4, wherein the K.sub.d of the aptamer to EGFR is at least 10.sup.2-fold greater based on the presence of the EGFR antagonist relative to the K.sub.d of the aptamer to free EGFR. 8. The aptamer of claim 1, wherein the aptamer binds to the extracellular domain of EGFR. 9. An aptamer that binds to EGFR comprising a nucleotide sequence selected from the group consisting of SEQ. ID. NOS: 1-54. 10. An aptamer that binds EGFR comprising a nucleotide sequence having at least 90% identity to anyone of the nucleotide sequences of SEQ ID NOs: 1-54.

Details for Patent 9,316,647

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2031-12-30
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2031-12-30
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2031-12-30